Michael Fort, chief executive of Synexus, said: “Once again our model has been shown to deliver the right numbers of patients at the right time even when it involves such a large scale logistical exercise. This was a complex late stage trial requiring mass screening of potential patients for randomization into the study. The company routinely screened over 1,000 patients a week for almost 12 months.
“Ultimately we were by far the largest clinical trials recruiter for this study, responsible for bringing in 23% of the patients in the global programme from less than 3% of the sites. All of our centres are equipped with state-of-the-art facilities including DEXA scanners. Our dedicated research centres, with full-time investigators are the way forward, helping us to recruit more quickly, and, in a big study, reducing set up and monitoring costs by millions of dollars.”
The company has been successfully running large scale phase III trials for a number of years, but believes that its recent acquisition, with an increase in capacity across Central and Eastern Europe, will persuade more sponsors to cornerstone their phase III trials with Synexus.
Jeremy Hickling, senior vice president of portfolio management, said: “We can already demonstrate our capacity to handle tens of thousands of screenings in a very short space of time, now that we have expanded our operations, this is only going to improve.”